Gestational diabetes mellitus
Gestational diabetes (GDM) is defined as any degree of glucose intolerance with onset during pregnancy and is associated with increased feto-maternal morbidity as well as long-term complications in mothers and offspring. Women detected to have diabetes early in pregnancy receive the diagnosis of overt, non-gestational, diabetes. GDM is diagnosed by an oral glucose tolerance test (OGTT) or fasting glucose concentrations (> 92 mg/dl). Screening for undiagnosed type 2 diabetes at the first prenatal visit (Evidence level B) is recommended in women at increased risk using standard diagnostic criteria (high risk: history of GDM or pre-diabetes (impaired fasting glucose or impaired glucose tolerance); malformation, stillbirth, successive abortions or birthweight > 4,500 g in previous pregnancies; obesity, metabolic syndrome, age > 45 years, vascular disease; clinical symptoms of diabetes (e.g. glucosuria). Performance of the OGTT (120 min; 75 g glucose) may already be indicated in the first trimester in some women but is mandatory between 24 and 28 gestational weeks in all pregnant women with previous non-pathological glucose metabolism (Evidence level B). Based on the results of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study GDM is defined, if fasting venous plasma glucose exceeds 92 mg/dl or 1 h 180 mg/dl or 2 h 153 mg/dl after glucose loading (OGTT; international consensus criteria). In case of one pathological value a strict metabolic control is mandatory. All women should receive nutritional counseling and be instructed in blood glucose self-monitoring. If blood glucose levels cannot be maintained in the normal range (fasting < 95 mg/dl and 1 h after meals < 140 mg/dl) insulin therapy should be initiated. Maternal and fetal monitoring is required in order to minimize maternal and fetal/neonatal morbidity and perinatal mortality. After delivery all women with GDM have to be reevaluated as to their glucose tolerance by a 75 g OGTT (WHO criteria) 6-12 weeks postpartum and every 2 years in case of normal glucose tolerance (Evidence level B). All women have to be instructed about their (sevenfold increased relative) risk of type 2 diabetes at follow-up and possibilities for diabetes prevention, in particular weight management and maintenance/increase of physical activity. Monitoring of the development of the offspring and recommendation of healthy lifestyle of the children and family is recommended.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2012 |
---|---|
Erschienen: |
2012 |
Enthalten in: |
Zur Gesamtaufnahme - volume:124 Suppl 2 |
---|---|
Enthalten in: |
Wiener klinische Wochenschrift - 124 Suppl 2(2012) vom: 18. Dez., Seite 58-65 |
Sprache: |
Deutsch |
---|
Weiterer Titel: |
Gestationsdiabetes (GDM) |
---|
Beteiligte Personen: |
Kautzky-Willer, Alexandra [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 08.08.2013 Date Revised 16.03.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.1007/s00508-012-0265-3 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM223540307 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM223540307 | ||
003 | DE-627 | ||
005 | 20231224060907.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2012 xx |||||o 00| ||ger c | ||
024 | 7 | |a 10.1007/s00508-012-0265-3 |2 doi | |
028 | 5 | 2 | |a pubmed24n0745.xml |
035 | |a (DE-627)NLM223540307 | ||
035 | |a (NLM)23250453 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a ger | ||
100 | 1 | |a Kautzky-Willer, Alexandra |e verfasserin |4 aut | |
245 | 1 | 0 | |a Gestational diabetes mellitus |
246 | 3 | 3 | |a Gestationsdiabetes (GDM) |
264 | 1 | |c 2012 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 08.08.2013 | ||
500 | |a Date Revised 16.03.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Gestational diabetes (GDM) is defined as any degree of glucose intolerance with onset during pregnancy and is associated with increased feto-maternal morbidity as well as long-term complications in mothers and offspring. Women detected to have diabetes early in pregnancy receive the diagnosis of overt, non-gestational, diabetes. GDM is diagnosed by an oral glucose tolerance test (OGTT) or fasting glucose concentrations (> 92 mg/dl). Screening for undiagnosed type 2 diabetes at the first prenatal visit (Evidence level B) is recommended in women at increased risk using standard diagnostic criteria (high risk: history of GDM or pre-diabetes (impaired fasting glucose or impaired glucose tolerance); malformation, stillbirth, successive abortions or birthweight > 4,500 g in previous pregnancies; obesity, metabolic syndrome, age > 45 years, vascular disease; clinical symptoms of diabetes (e.g. glucosuria). Performance of the OGTT (120 min; 75 g glucose) may already be indicated in the first trimester in some women but is mandatory between 24 and 28 gestational weeks in all pregnant women with previous non-pathological glucose metabolism (Evidence level B). Based on the results of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study GDM is defined, if fasting venous plasma glucose exceeds 92 mg/dl or 1 h 180 mg/dl or 2 h 153 mg/dl after glucose loading (OGTT; international consensus criteria). In case of one pathological value a strict metabolic control is mandatory. All women should receive nutritional counseling and be instructed in blood glucose self-monitoring. If blood glucose levels cannot be maintained in the normal range (fasting < 95 mg/dl and 1 h after meals < 140 mg/dl) insulin therapy should be initiated. Maternal and fetal monitoring is required in order to minimize maternal and fetal/neonatal morbidity and perinatal mortality. After delivery all women with GDM have to be reevaluated as to their glucose tolerance by a 75 g OGTT (WHO criteria) 6-12 weeks postpartum and every 2 years in case of normal glucose tolerance (Evidence level B). All women have to be instructed about their (sevenfold increased relative) risk of type 2 diabetes at follow-up and possibilities for diabetes prevention, in particular weight management and maintenance/increase of physical activity. Monitoring of the development of the offspring and recommendation of healthy lifestyle of the children and family is recommended | ||
650 | 4 | |a English Abstract | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Hypoglycemic Agents |2 NLM | |
650 | 7 | |a Insulin |2 NLM | |
700 | 1 | |a Bancher-Todesca, Dagmar |e verfasserin |4 aut | |
700 | 1 | |a Pollak, Arnold |e verfasserin |4 aut | |
700 | 1 | |a Repa, Andreas |e verfasserin |4 aut | |
700 | 1 | |a Lechleitner, Monika |e verfasserin |4 aut | |
700 | 1 | |a Weitgasser, Raimund |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Wiener klinische Wochenschrift |d 1946 |g 124 Suppl 2(2012) vom: 18. Dez., Seite 58-65 |w (DE-627)NLM000045071 |x 1613-7671 |7 nnns |
773 | 1 | 8 | |g volume:124 Suppl 2 |g year:2012 |g day:18 |g month:12 |g pages:58-65 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00508-012-0265-3 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 124 Suppl 2 |j 2012 |b 18 |c 12 |h 58-65 |